← Kiniksa Pharmaceuticals International, plc KNSA
Market Price
$76.79
Market Cap
$5.99B
P/E Ratio
102.39
Revenue (FY 2025)
↑60.1% YoY
$677.56M
3-Yr CAGR: 45.5%
Net Income
↑236.6% YoY
$59.01M
Net Margin: 8.7%
Free Cash Flow
↑436.8% YoY
$136.42M
FCF Yield: 2.28%
EPS (Diluted)
↑225.0% YoY
$0.75
Basic: $0.80
Return on Equity
Efficiency
10.4%
ROA: 7.7%
📊 Multi-Year Historical Performance & Trends
Financial Performance History
Revenue, Net Income & Free Cash Flow
Margins Trend (%)
Gross, Operating & Net Margins
Balance Sheet Strength
Cash, Debt & Equity
Cash Flow Generation
Operating Cash Flow vs CapEx vs FCF
📈 Year-over-Year (YoY) Growth History (KNSA)
All monetary values in millions ($M)| Fiscal Year | Revenue | Revenue YoY | Gross Profit | Net Income | Net Inc YoY | Diluted EPS | EPS YoY | Op. Cash Flow | Free Cash Flow | FCF YoY |
|---|---|---|---|---|---|---|---|---|---|---|
| FY 2016 | — | — | — | $-1.5M | — | $-0.01 | — | $-0.9M | — | — |
| FY 2017 | — | — | — | $-64.9M | -4,139.0% | $-35.85 | -358,400.0% | $-50.2M | $-50.3M | — |
| FY 2018 | — | — | — | $-103.2M | -59.1% | $-3.49 | +90.3% | $-81.0M | $-86.3M | -71.6% |
| FY 2019 | — | — | — | $-161.9M | -56.8% | $-2.99 | +14.3% | $-158.4M | $-161.6M | -87.2% |
| FY 2020 | — | — | — | $-161.4M | +0.3% | $-2.61 | +12.7% | $-136.5M | $-136.8M | +15.3% |
| FY 2021 | $38.5M | — | $29.4M | $-157.9M | +2.1% | $-2.30 | +11.9% | $-126.3M | $-126.7M | +7.4% |
| FY 2022 | $220.2M | +471.2% | $173.2M | $183.4M | +216.1% | $2.60 | +213.0% | $5.8M | $5.7M | +104.5% |
| FY 2023 | $270.3M | +22.7% | $180.3M | $14.1M | -92.3% | $0.20 | -92.3% | $13.3M | $13.2M | +131.0% |
| FY 2024 | $423.2M | +56.6% | $362.3M | $-43.2M | -406.7% | $-0.60 | -400.0% | $25.7M | $25.4M | +92.9% |
| FY 2025 | $677.6M | +60.1% | $599.9M | $59.0M | +236.6% | $0.75 | +225.0% | $138.0M | $136.4M | +436.8% |
Valuation
Market Price
$76.79
Market Cap
$5.99B
Enterprise Value
N/A
P/E Ratio
102.39
P/B Ratio
10.41
FCF Yield
2.28%
Dividend Yield
N/A
Shares Outstanding
Profitability & Margins
Gross Margin
88.54%
Operating Margin
11.40%
Net Margin
8.71%
Return on Equity (ROE)
10.40%
Return on Assets (ROA)
7.73%
Asset Turnover
0.89x
Revenue 3-Yr CAGR
45.45%
Financial Health & Liquidity
Current Ratio
1.01
Cash Ratio
3.94
Debt / Equity
N/A
Debt / Assets
N/A
Cash & Equivalents
$165.60M
Total Debt
N/A
Book Value / Share
$7.38
Cash Flow Efficiency
Operating Cash Flow
$137.99M
Capital Expenditures (CapEx)
$1.57M
Free Cash Flow
$136.42M
OCF / Revenue
20.36%
FCF / Revenue
20.13%
FCF 3-Yr CAGR
188.15%
Per Share Metrics
EPS (Diluted)
$0.75
EPS (Basic)
$0.80
Dividends / Share
N/A
Book Value / Share
$7.38
EPS YoY Growth
225.00%
Balance Sheet (FY 2025)
Total Assets
$763.63M
Total Liabilities
$196.03M
Stockholders' Equity
$567.61M
Current Assets
$42.61M
Current Liabilities
$42.02M